Eric Dube, Ph.D.

Eric Dube, Ph.D.

President, Chief Executive Officer and DirectoratTravere Therapeutics· In proxies 2021–2025

Pay in FY2025Travere Therapeutics stock +119.3% the same year

Eric Dube, Ph.D. was paid $8.5M in FY2025 (Dec). Travere Therapeutics stock rose 119.3% that year.

Pay$100 in the stock at the end of FY20 → $169
Pay is from the Summary Compensation Table of each Travere Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Travere TherapeuticsPublic company · 5 yr
    • President, Chief Executive Officer and Director2021 – Present · 5 yrStock in role +84%
  2. Directors for the Biotechnology Innovation OrganizationPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years
  3. Reneo Pharmaceuticals, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Directors for Biocom CaliforniaPublic company
    • Director? – PresentNo stock prices for these years
  5. Directors for Reneo Pharmaceuticals, Inc.Public company · 3 yr
    • Director2021 – 2024 · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?